Article Text

PDF
A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer
  1. Serena Venturelli,
  2. Elizabeth Okecha
  1. HIV/GUM Specialty Registrars, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK; serena.venturelli@chelwest.nhs.ukelizabeth.okecha@nhs.net

Statistics from Altmetric.com

Graham DM, Isaranuwatchai W, Habbous S, et al. Cancer. Published Online First: 13 April 2015. doi:10.1002/cncr.29111

The human papillomavirus (HPV) is an oncogenic virus associated with anogenital and head and neck cancers in both sexes. HPV vaccination has already been introduced in the national immunisation programmes of 63 countries to prevent cervical cancer;1 however, few countries are recommending HPV vaccination for male patients.

There are limited published data on the benefit of male HPV vaccination in preventing extra-genital HPV-related cancers. Furthermore, the efficacy of HPV vaccination in preventing oropharyngeal carcinoma (OPC) is as yet undemonstrated due to a …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.